Drawing for NIASPAN

USPTO serial 78711536

NIASPAN

Reviewed by CopyMark Law Group

Reg. 3141685Status 710
Filing date
Status date
Registration date
Sep 12, 2006
Examiner
RINKER, ANTHONY MICHAEL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with NIASPAN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nicole Hickey

Nicole Hickey Abbott Laboratories100 Abbott Park RoadD377/AP6AAbbott Park, IL 60064-6008

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of arteriosclerotic diseases, autoimmune diseases, cancer, cardiovascular diseases, central nervous system diseases and disorders, cerebrovascular diseases, diabetes and other metabolic disorders, inflammation and inflammatory diseases, respiratory and infectious diseases, peripheral and central vascular diseases, seizure disorders, shock and central nervous system trauma, stroke, and viral diseasesSECTION 8 - CANCELLEDJan 28, 2002
016Printed instructional, educational, and teaching materials in the field of pharmaceutical preparations for the treatment of lipid disorders, arteriosclerosis and cardiovascular diseasesSECTION 8 - CANCELLEDJan 28, 2002

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 19, 2013C8..CANCELLED SEC. 8 (6-YR)—
Aug 13, 2008ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Feb 20, 2008ASCKASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY—
Apr 27, 2007ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 27, 2007REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 12, 2006R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 20, 2006PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 31, 2006NPUBNOTICE OF PUBLICATION—
May 1, 2006PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY—
Apr 5, 2006PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 31, 2006ALIEASSIGNED TO LIE—
Mar 29, 2006CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 24, 2006XAECEXAMINER'S AMENDMENT ENTERED—
Mar 24, 2006GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 24, 2006CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 23, 2006DOCKASSIGNED TO EXAMINER—
Nov 14, 2005MAILPAPER RECEIVED—
Sep 20, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance